Preview

User

Not a user? Register with this site Forgot your password?

Russian Journal of Gastroenterology, Hepatology, Coloproctology

Advanced search

Results of the Interdisciplinary International Expert Council on Addressing the Management of Patients with Non-Alcoholic (Metabolic Dysfunction- Associated) Fatty Liver Disease

https://doi.org/10.22416/1382-4376-2026-36-3-7-20

Abstract

Aim: to present the results of an interdisciplinary international expert council on addressing the challenges of managing patients with non-alcoholic (metabolic dysfunction-associated) fatty liver disease in connection with the creation of a new nomenclature, the definition of diagnostic criteria, and the development of approaches to the diagnosis and treatment of fatty liver disease.

Key points. The key role of metabolic dysfunction in non-alcoholic (metabolic dysfunction-associated) fatty liver disease has been proven. Therefore, in the nomenclature, non-alcoholic fatty liver disease (NAFLD) has been replaced by metabolic dysfunction-associated fatty liver disease, and non-alcoholic steatohepatitis has been replaced by metabolic dysfunction-associated steatohepatitis. It is noted that, according to research, the prevalence of fatty liver disease in Russia is high: one-third of patients seeking primary care have this diagnosis. The results of a study of two incretin mimetics, semaglutide and tirzepatide, are presented, along with an opinion on their rational combination with ursodeoxycholic acid. The comorbidity of fatty liver disease with cardiovascular, endocrine, and oncological diseases, chronic kidney disease, and other conditions is discussed.

Conclusion. The expert council included leading specialists: gastroenterologists-hepatologists, cardiologists, internists, and endocrinologists. There were confirmed that treatment for fatty liver disease should be comprehensive and integrated into the overall concept of metabolic health. Algorithms for diagnosis and personalized treatment of fatty liver disease have to be developed for the Russian medical community.

About the Authors

M. V. Maevskaya
I I.M. Sechenov First Moscow State Medical University (SechenovUniversity)
Russian Federation

Marina V. Maevskaya* — Dr. Sci. (Med.), Professor, Vice-President of the Russian Scientific Liver
Society

119991, Moscow, GSP-1, Trubetskaya str., 8/2


S. V. Okovityi
Saint Petersburg State Chemical and Pharmaceutical University
Russian Federation

Sergey V. Okovityi — Dr. Sci. (Med.), Professor, Head of the Department of Pharmacology and Clinical Pharmacology

197022, St. Petersburg, Professora Popova str., 14А


I. G. Bakulin
NorthWestern State Medical University named after I.I. Mechnikov
Russian Federation

Igor G. Bakulin — Dr. Sci. (Med.), Professor, Head of the Department of Propaedeutics of Internal Medicine, Gastroenterology and Dietetics named after S.M. Ryss

191015, St. Petersburg, Kirochnaya str., 41


A. S. Bidzhiev
Center for Hepatopancreatobiliary Surgery, Oncohepatology and Organ Transplantation, National Scientific Oncology Cente
Kazakhstan

Alan S. Bidzhiev — Gastroenterologist

010017, Republic of Kazakhstan, Astana, Kerey and Zhanibek
Khandar Street, 3/2


D. V. Glushenkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Dmitriy V. Glushenkov — Cand. Sci. (Med), Head of the Medical and Diagnostic Department No. 3 with the Functions of the Admission Department

119991, Moscow, GSP-1, Trubetskaya str., 8/2


O. Yu. Gurova
Professorial Clinic of Endocrinology and Diabetes
Russian Federation

Olesya Yu. Gurova — Cand. Sci. (Med.), Chief Physician

119334, Moscow, Andreevskaya emb., 1, build. 1


A. Yu. Gorshkov
National Medical Research Center for Therapy and Preventive Medicine

Alexander Yu. Gorshkov — Cand. Sci. (Med.), Deputy Director for Scientific and Outpatient Clinical Work

101990, Moscow, Petroverigsky Lane, 10, build. 3


V. A. Zhakipbekova
Karaganda Medical University
Kazakhstan

Venera A. Zhakipbekova — Cand. Sci. (Med.), Docent, Associate Professor

100000, Republic of Kazakhstan, Karaganda, Gogolya str., 40


O. Yu. Zolnikova
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)
Russian Federation

Oxana Yu. Zolnikova — Dr. Sci. (Med.), Professor at the Department of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Leading Researcher at the Scientific and Technological Institute of Metabolic Health

119991, Moscow, GSP-1, Trubetskaya str., 8/2


M. M. Karimov
Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation
Uzbekistan

Mirvasit M. Karimov — Dr. Sci. (Med.), Professor, Chief Gastroenterologist of Ministry of Health of the Republic of Uzbekistan, Head of the Gastroenterology Department

100052, Republic of Uzbekistan, Tashkent, Osiyo str., 4


Yu. V. Kotovskaya
N.I. Pirogov Russian National Research Medical University
Russian Federation

Yulia V. Kotovskaya — Dr. Sci. (Med.), Professor, Deputy Director for Scientific Affairs at the Russian Clinical and Research Center of Gerontology; Head of the Department for the Implementation of Functions of the National Medical Research Center for Geriatrics

129226, Moscow, Pervaya Leonova str., 16


I. V. Maev
Russian University of Medicine
Russian Federation

Igor V. Maev — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Science, Head of the Department of Internal Disease Propaedeutics and Gastroenterology, Faculty of Medicine

127473, Moscow, Delegatskaya str., 20, build. 


R. V. Maslennikov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Roman V. Maslennikov — Cand. Sci. (Med.), Associate Professor at the Department of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Leading Researcher at the Scientific and Technological Institute of Metabolic Health

119991, Moscow, GSP-1, Trubetskaya str., 8/2


M. Yu. Nadinskaia
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Maria Yu. Nadinskaia — Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutics of Internal Diseases

119991, Moscow, GSP-1, Trubetskaya str., 8/2


M. F. Osipenko
Novosibirsk State Medical University
Russian Federation

Marina F. Osipenko — Dr. Sci. (Med.), Professor, Head of the Department of Internal Diseases Propedeutics

630091, Novosibirsk, Krasnyi ave., 52


K. L. Raikhelson
Saint Petersburg State University; Academician I.P. Pavlov First Saint Petersburg State Medical University
Russian Federation

Karina L. Raikhelson — Dr. Sci. (Med.), Docent, Professor of Scientific and Educational Center of Gastroenterology and Hepatology of the Medical Institute;  Professor of Department of General Medical Practice (Family Medicine)

199106, Saint Petersburg, 21-ya Liniya Vasilyevskogo Ostrova, 8a


B. P. Sultanova
Research Institute of Cardiology and Internal Medicine
Kazakhstan

Balnur P. Sultanova — MD, PhD, 1st Category Endocrinologist, Acting Associate Professor of the Department of Endocrinology

050000, Republic of Kazakhstan, Almaty, Aiteke Bi Street, 120


O. N. Tkacheva
N.I. Pirogov Russian National Research Medical University
Russian Federation

Olga N. Tkacheva — Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

117997, Moscow, Ostrovityanova str., 1


E. A. Troshina
Endocrinology Research Centre
Russian Federation

Ekaterina A. Troshina — Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Director of the Institute of Clinical Endocrinology, Deputy Director

117292, Moscow, Dmitrya Ulyanovs str., 11


Z. Yu. Khalimova
Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Acad. Y.Kh. Turakulov
Kazakhstan

Zamira Yu. Khalimova — Dr. Sci. (Med.), Deputy Director for Science, Head of the Department of Neuroendocrinology with Pituitary Neurosurgery

100125, Republic of Uzbekistan, Tashkent, Mirzo Ulugbek Ave., 56


G. A. Khamidullaeva
Republican Specialized Scientific and Practical Medical Center of Cardiology
Uzbekistan

Gulnoz A. Khamidullaeva — Dr. Sci. (Med.), Professor, Head of the Department of Arterial Hypertension

100052, Republic of Uzbekistan, Tashkent, Osiyo str., 4


A. F. Sheptulina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Anna F. Sheptulina — Cand. Sci. (Med.), Leading Researcher, Head of the Laboratory of Experimental and Preventive Gastroenterology

101000, Moscow, Petroverginskiy lane, 10, build. 3


E. N. Shirokova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Elena N. Shirokova — Dr. Sci. (Med.), Professor at the Department of Internal Disease Propaedeutics, Gastroenterology and Hepatology

119991, Moscow, GSP-1, Trubetskaya str., 8/2


O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Oksana M. Drapkina — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Director; President of the Russian Society for the Prevention of NonCommunicable Diseases; President of the Russian Scientific Medical Society of Therapists; Chief Specialist in Therapy and General Medical Practice

101000, Moscow, Petroverginskiy lane, 10, build. 3


V. T. Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Vladimir T. Ivashkin — Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Internal Disease Propaedeutics, Gastroenterology and Hepatology of the N.V. Sklifosovsky Institute of Clinical Medicine, Head of the Scientific and Technological Institute of Metabolic Health

119991, Moscow, GSP-1, Trubetskaya str., 8/2


References

1. Raikhelson K.L., Maevskaya M.V., Zharkova M.S., Grechishnikova V.R., Okovityi S.V., Deeva T.A., et al. Steatotic liver disease: New nomenclature and its localization in the Russian Federation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):35–44. (In Russ.)]. DOI: 10.22416/1382-4376-2024-961

2. World Health Organization. Noncommunicable diseases. URL: https://www.who.int/ru/health-topics/noncommunicable-diseases#tab=tab_1

3. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., et al.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86. DOI: 10.1097/HEP.0000000000000520

4. Liu Z., Lin C., Suo C., Zhao R., Jin L., Zhang T., et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2021;127:154955. DOI: 10.1016/j.metabol.2021.154955

5. Drapkina O.M., Evstifeeva S.E., Shalnova S.A., Kutsenko V.A., Balanova Yu.A., Imaeva A.E., et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies). Cardiovascular Therapy and Prevention. 2025;24(2):4316. (In Russ.)]. DOI: 10.15829/1728-8800-2025-4316

6. Dicheva D.T., Brekhunets R.M., Andreev D.N., Lebedeva E.G., Berezutskaya O.E., Golovkina N.L., et al. Prevalence of non-alcoholic fatty liver disease at Moscow multi-speciality hospitals from 2022 to 2024. Medical Council. 2025;(15):149–55. (In Russ.)]. DOI: 10.21518/ms2025-401

7. Mladenova I.L., Tan E.F., Ng J.Y., Sharma P. Non- alcoholic fatty liver disease (NAFLD) and its association to cardiovascular disease: A comprehensive meta-analysis. JRSM Cardiovasc Dis. 2025;14:20480040251325929. DOI: 10.1177/20480040251325929

8. Liao Y.L., Zhu G.Y., Chang C. Non-alcoholic fatty liver disease increases the risk of cardiovascular disease in young adults and children: A systematic review and meta-analysis of cohort studies. Front Cardiovasc Med. 2024;10:1291438. DOI: 10.3389/fcvm.2023.1291438

9. Clayton-Chubb D., Roberts S.K., Majeed A., Woods R.L., Tonkin A.M., Nelson M.R., et al. Associations between MASLD, atrial fibrillation, cardiovascular events, mortality and aspirin use in older adults. Geroscience. 2025;47(1):1303–18. DOI: 10.1007/s11357-024-01435-2

10. Ivashkin V.T., Drapkina O.M., Maevskaya M.V., Raikhelson K.L., Okovityi S.V., Zharkova M.S., et al. Clinical guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on non-alcoholic fatty liver disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2025;35(1):94–152. (In Russ.)]. DOI: 10.22416/1382-4376-2025-35-1-94-152

11. Sanyal A.J., Newsome P.N., Kliers I., Østergaard L.H., Long M.T., Kjær M.S., et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089–99. DOI: 10.1056/NEJMoa2413258

12. Loomba R., Hartman M.L., Lawitz E.J., Vuppalanchi R., Boursier J., Bugianesi E., et al.; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299–310. DOI: 10.1056/NEJMoa2401943

13. Amaral J.D., Viana R.J., Ramalho R.M., Steer C.J., Rodrigues C.M. Bile acids: Regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50(9):1721– 34. DOI: 10.1194/jlr.R900011-JLR200

14. Guo C., Chen W.D., Wang Y.D. TGR5, not only a metabolic regulator. Front Physiol. 2016;7:646. DOI: 10.3389/ fphys.2016.00646

15. Tang Y., Blomenkamp K.S., Fickert P., Trauner M., Teckman J.H. NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. PLoS ONE. 2018;13(8):e0200897. DOI: 10.1371/journal.pone.0200897

16. Da Silva J.A. Jr., Figueiredo L.S., Chaves J.O., Oliveira K.M., Carneiro E.M., Abreu P.A., et al. Effects of tauroursodeoxycholic acid on glucose homeostasis: Potential binding of this bile acid with the insulin receptor. Life Sci. 2021;285:120020. DOI: 10.1016/j.lfs.2021.120020

17. Fiorucci S., Distrutti E., Carino A., Zampella A., Biagioli M. Bile acids and their receptors in metabolic disorders. Prog Lipid Res. 2021;82:101094. DOI: 10.1016/j.plipres.2021.101094

18. Shima K.R., Ota T., Kato K.I., Takeshita Y., Misu H., Kaneko S., et al. Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: A pilot randomized controlled and add-on study. BMJ Open Diabetes Res Care. 2018;6(1):e000469. DOI: 10.1136/bmjdrc-2017-000469

19. Foo R.X., Ma J.J., Du R., Goh G.B.B., Chong Y.S., Zhang C., et al. Gestational diabetes mellitus and development of intergenerational non-alcoholic fatty liver disease (NAFLD) after delivery: A systematic review and meta-analysis. EClinicalMedicine. 2024;72:102609. DOI: 10.1016/j.eclinm.2024.102609

20. Vounzoulaki E., Khunti K., Abner S.C., Tan B.K., Davies M.J., Gillies C.L. Progression to type 2 diabetes in women with a known history of gestational diabetes: Systematic review and meta-analysis. BMJ. 2020;369:m1361. DOI: 10.1136/bmj.m1361

21. Nadinskaia M., Maevskaya M., Ivashkin V., Kodzoeva K., Pirogova I., Chesnokov E., et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959–75. DOI: 10.3748/wjg.v27.i10.959

22. Cao X., Zolnikova O.Yu., Maslennikov R.V., Poluektova E.A., Bueverova E.L., Reshetova M.S., et al. Metabolic profiles of the gut microbiota in patients with different stages of metabolism dysfunction- associated fatty liver disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(4):64–74. (In Russ.)]. DOI: 10.22416/1382-4376-2024-34-4-64-74

23. Cao X., Zolnikova O., Maslennikov R., Reshetova M., Poluektova E., Bogacheva A., et al. Differences in fecal short-chain fatty acids between alcoholic fatty liver- induced cirrhosis and non-alcoholic (metabolic-associated) fatty liver-induced cirrhosis. Metabolites. 2023;13(7):859. DOI: 10.3390/metabo13070859

24. Reshetova M.S., Markin P.A., Appolonova S.A., Shestakova K.M., Baydalin O.A., Voloshin I.A., et al. Metabolomic profiling of patients with alcoholic liver disease and non-alcoholic fatty liver disease using principal component analysis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2025;35(3):54–70. (In Russ.)]. DOI: 10.22416/1382-4376-2025-35-3-54-70

25. Reshetova M., Markin P., Appolonova S., Yunusov I., Zolnikova O., Bueverova E., et al. Tryptophan metabolites in the progression of liver diseases. Biomolecules. 2024;14(11):1449. DOI: 10.3390/biom14111449

26. Su X., Chen S., Liu J., Feng Y., Han E., Hao X., et al. Composition of gut microbiota and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Obes Rev. 2024;25(1):e13646. DOI: 10.1111/obr.13646


Review

For citations:

Maevskaya M.V., Okovityi S.V., Bakulin I.G., Bidzhiev A.S., Glushenkov D.V., Gurova O.Yu., Gorshkov A.Yu., Zhakipbekova V.A., Zolnikova O.Yu., Karimov M.M., Kotovskaya Yu.V., Maev I.V., Maslennikov R.V., Nadinskaia M.Yu., Osipenko M.F., Raikhelson K.L., Sultanova B.P., Tkacheva O.N., Troshina E.A., Khalimova Z.Yu., Khamidullaeva G.A., Sheptulina A.F., Shirokova E.N., Drapkina O.M., Ivashkin V.T. Results of the Interdisciplinary International Expert Council on Addressing the Management of Patients with Non-Alcoholic (Metabolic Dysfunction- Associated) Fatty Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2026;36(3):7-20. https://doi.org/10.22416/1382-4376-2026-36-3-7-20

Views: 90

JATS XML

ISSN 1382-4376 (Print)
ISSN 2658-6673 (Online)

Tatiana L. Lapina - MD, PhD, associate professor, Department of Internal Diseases Propedeutics,
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
119146,  Moscow, PO box 31
e-mail: editorial@gastro-j.ru, tatlapina@gmail.com
tel.: +79031926919

Processing of personal data
supported by NEICON (Elpub lab)